Incheon, South Korea – October 16, 2025 – CelltrionUSA, a subsidiary of Celltrion Inc., announced that the U.S. Food and Drug Administration (FDA) has approved expanded indications for YUFLYMA® (adalimumab-aaty) and its unbranded version to treat adolescent hidradenitis suppurativa (HS) and pediatric non-infectious uveitis (UV). This marks a major regulatory milestone in the company’s ongoing mission to broaden access to biosimilar biologic therapies for younger patient populations.
Science Significance
This FDA decision underscores the scientific advancement of biosimilar antibody technology, validating YUFLYMA’s therapeutic equivalence to the reference adalimumab across inflammatory and autoimmune conditions. The inclusion of pediatric HS and UV expands the body of clinical data supporting adalimumab’s efficacy and safety in immuno-modulated disorders. Celltrion’s formulation uses a high-concentration, citrate-free profile to improve injection comfort and maintain robust immunogenicity control, making it a next-generation option for pediatric immunology.
Regulatory Significance
The expanded approval reinforces the FDA’s confidence in biosimilar development pathways and strengthens Celltrion’s regulatory standing in the U.S. market. This clearance highlights the success of global harmonization efforts under the Biosimilars Action Plan, encouraging more streamlined submission processes for biologics. The decision also supports post-marketing safety surveillance as part of Celltrion’s continued adherence to cGxP and pharmacovigilance standards, demonstrating its regulatory compliance and transparency in pediatric therapeutics.
Business Significance
Advertisement
With the addition of pediatric indications, YUFLYMA’s market potential in the United States is expected to rise significantly. The decision enables CelltrionUSA to broaden its product portfolio, targeting a wider base of healthcare providers and insurers focused on cost-effective biologic substitution. This regulatory expansion enhances the company’s strategic positioning within the competitive adalimumab biosimilar landscape, where affordability and reliability play key roles in securing hospital and clinic adoption.
Patients’ Significance
The approval delivers important therapeutic options for pediatric and adolescent patients suffering from debilitating immune-mediated diseases. HS and UV can severely impact quality of life and vision in young individuals; with this decision, children and teens will now have access to a clinically proven biologic at a lower cost. The high-concentration, citrate-free formulation reduces injection volume and discomfort, improving treatment adherence and overall patient experience.
Policy Significance
This development aligns with U.S. healthcare policy goals to expand biosimilar access, reduce biologic drug costs, and promote equitable treatment options for all age groups. The approval supports the FDA’s commitment to innovation in pediatric care and the Biden administration’s broader efforts to lower prescription drug spending. Furthermore, it exemplifies the role of biosimilars in achieving sustainable healthcare economics without compromising safety or efficacy.
The FDA’s pediatric indication expansion for YUFLYMA marks another milestone in Celltrion’s journey toward accessible, high-quality biopharmaceuticals. By combining rigorous science, regulatory integrity, and patient-centered innovation, the company continues to advance affordable biologic care for complex immune disorders. As biosimilars increasingly reshape therapeutic access worldwide, Celltrion’s pediatric approval sets a new precedent for scientific, ethical, and economic progress in modern biologics.
Source: Celltrion press release
